Experts in Access
We have over 40 years of finding solutions for companies like you.
Managing Partner, LatticePoint
Sean Robbins has more than 20 years of experience in pricing and reimbursement in the pharmaceutical industry.
He has launched several products globally; and developed pricing and market access strategies for pharmaceutical products across the lifecycle. Most recently, he has developed strategies; and has been the primary lead for execution for the reimbursement for more than 15 ODD products in EU. He has been a thought leader in developing strategies and tactics to combat International Reference Pricing; and providing advice to companies about what they can do to better prepare for reference pricing.
He is the author of several publications in clinical and health economics journals; and has been involved in the development of pricing defence strategies for several of the early biosimilars launched in Europe. He was one of the only early advocates in pharma to institute value-based selling programs with “the field”; bringing Pricing Function and Key Account Management teams closer together to fostering shared goals in pricing execution. Sean is currently an Adjunct Professor at the University of Southern California in the Titus School of Pharmacy and Health Policy where he teaches pharmaceutical pricing and reimbursement. Sean is passionate about introducing profit enhancing pricing analytics and novel market access strategies into pharmaceutical companies to help drive improvements in company’s bottom line.
Ted joined LatticePoint in July 2016 and provides advisory services to early-stage companies in the cell and gene therapy space and has advised on market access, EMA Adaptive Pathways, international expansion, talent acquisition, and key customer relationships.
Prior to consulting, he spent 17 years working in the pharmaceutical industry and headed the Market Access function for Genzyme’s Rare Disease Business Unit and Pfizer’s Head of Head of Market Access, Primary Care BU. Before joining Pfizer, he spent 7 years at Schering-Plough in various regional and affiliate finance roles.
Ted began his career at Deloitte & Touche, including two years in Frankfurt, Germany and is a qualified SEC Audit Committee Financial Expert.
He is a frequent speaker on gene therapy pricing and has published on reforming payment for cell and gene therapies with colleagues from the Alliance for Regenerative Medicine.
He has a BS degree in accounting from Villanova University, a Master of Arts in International Affairs from The Fletcher School of Law & Diplomacy at Tufts University, and an MBA from the Leonard N. Stern School of Business at New York University. He speaks fluent German in addition to his native English.
Director Pricing & Reimbursement Strategy
Karin develops market access strategies and value-based communication tools for innovative orphan medicines entering European and North American markets. She has supported business development models and due diligence for business development departments.
At LatticePoint, she is further responsible for recruitment, training of new hires and team development.
Prior to consulting, Karin performed fundamental and translational research in the fields of infectious, autoimmune and neurodegenerative diseases. During her scientific career, she led several research projects, including the development of new animal models for autoimmune diseases and research of new strategies to prevent viral infections. Her research contributed to the identification of new drug targets for the treatment of multiple sclerosis, which are now in development. She has contributed to patent applications, obtained prestigious awards for her research and authored several high-impact publications.
Jordi joined LatticePoint in 2024. He holds a PhD in Biomedicine from the Universitat Autonoma de Barcelona, Spain and an executive MBA from ESADE law and business school.
He has been involved in +30 strategy and M&A projects. He has specialized in biotech and pharma companies, as well as CDMOs. He has worked for public and private companies, listed in EU and US, as well as Fortune500 companies and biotech unicorns. He has worked in different drug modalities, being very active in nuclear medicine and advanced therapy space.
He has more than 10 years of experience in scientific research, with a bachelor in biotechnology and a master in neuroscience. He obtained his PhD in 2016 at the CRG. After his postdoctoral experience, Jordi started working as an entrepreneur in residence, he is an inventor and co-founder of a biotech developing novel RNA modifying compounds for the treatment of oncological malignancies.
In addition to his scientific and entrepreneurship experience, Jordi holds an executive MBA from ESADE, law and business school.
Jordi has been awarded several grants and prices, like La Caixa International PhD Fellowship program and CERCA Pioneer Price for his thesis, Caixa Impulse 2017, European Research Council Proof of Concept 2017, Industria del Coneixement Producte 2018, Worldwide Cancer Research UK, Caixa Impulse Consolidate 2021, and EIC Transition.
Senior Consultant Market Access & Pricing
Ela joined LatticePoint in 2020. She holds a PhD in Biomedicine from the University of Barcelona, Spain.
Ela joined LatticePoint with the aim of using her scientific skill set to help tackle issues closer to patient’s bedside. At LatticePoint she translated her excitement about the multidimensional nature of market access field into support of market access strategy projects for different European healthcare systems. Ela performs primary and secondary research, develops value communication tools, and contributes to writing of reimbursement dossiers and scientific publications as well as development of health economic models. During her time at LatticePoint, she built knowledge in disease areas like oncology, infectious diseases, and autoimmune disorders, and explored the world of advanced medicine therapies. Ela appreciates strategy-oriented discussions and an environment that promotes growth.
Before transitioning into consulting, Ela was a scientist in molecular biophysics field. She obtained a PhD from the University of Barcelona in Spain. In her research she focused on a question – what can we understand about intrinsically disordered proteins to change their label from undruggable to druggable? Investigation of the question led to several publications leaving her ready for new challenges.
Senior Consultant Market Access & Pricing
Heinz joined LatticePoint in 2016. Heinz received his M.Sc. in Bioengineering from the Swiss Federal Institute of Technology (EPFL) in Lausanne, Switzerland.
Heinz supports pharmaceutical and medical device companies across their product life cycle in Europe and the US. Starting with competitive landscape analysis and indication assessments, to creating and testing of value propositions and TPPs using primary and secondary research. He provides insights with market forecast, budget impact and cost-effectiveness analysis and can advise you on price strategy and governance. Furthermore he can help you with launch sequence planning and optimization. Experienced in writing value and reimbursement dossiers, he can assist you to bring your product to the market. He is motivated to find creative and tailored solution and convey them to payers for you. Heinz has experience in interacting with multiple governmental agencies, including CMS.
At LatticePoint, he further supports recruitment, internal training and external communication.
Consultant Market Access & Pricing
Benjamin has practical experience developing cost-effectiveness models in Excel or R. He also designed modeling, analysis, and data visualization tools targeting internal and external audiences.
Additionally, Benjamin has hands-on experience with value-based pricing, evidence gap analysis, and pipeline prioritization for multi-indication assets. He also contributed to writing European reimbursement dossiers. He participated in projects that evaluated the impact of new regulations, such as the new EU Pharma strategy and IRA, on access and pricing of oncology products.
Before joining LatticePoint, Benjamin worked as an associate scientist at Debiopharm International. He was a project leader at Transcure bioServices, overseeing in vivo immune-oncology studies for international pharmaceutical clients.
Consultant Market Access & Pricing
At LatticePoint, Efe is responsible for market access in Turkey, developing tailored pricing and reimbursement strategies, and providing life-cycle support for medicinal products. He is also responsible for the retained payer panel database with a large collection of key stakeholders ranging from payers, prescribers, HTA advisors to medical key opinion leaders in US, Europe and parts of Asia.
Efe supports the development of payer value propositions, reimbursement dossiers, and evidence generation plans for innovative medicines entering the European market. Particularly, he has experience in writing reimbursement dossiers in the Netherlands. He also works on identifying sources of high-quality epidemiological, clinical, and real-world data.
Before moving into the consulting sector, Efe was specialized in cell-based therapies against malignant cancers. Efe developed and optimized T cell receptor affinity-engineered CD8 T cells targeting melanoma. Due to his scientific background, he is particularly interested in cell-based therapies, immune-checkpoint inhibitors, and other oncology medicines.
Consultant Health Economics
During her PhD, she carried out different projects focusing on behavioral biases in economic decision making. In particular, she investigated the impact of overconfidence on negotiation outcomes, experimentally and by means of theoretic models. Moreover, in her early researcher experience, she explored economic market dynamics in agent-based models empirically parametrized.
Consultant Market Access & Pricing
Johannes joined LatticePoint in 2023. He obtained an M.Sc. in physics from the RWTH Aachen University (Germany) and a PhD for work in medical physics at the European Organization for Nuclear Research (CERN), Switzerland, and RWTH Aachen University.
Johannes has more than 6 years of experience in R&D of medical devices, gained during his PhD and post-doc work. His research was based at CERN and focused on detector development for radiation therapy of cancer patients.
In addition, Johannes has 1.5 years of experience in a consulting company for regulatory affairs for medical devices, where he established regulatory pathways (mainly for the EU and the USA), defined clinical strategies, and performed and reviewed clinical evaluations for medical devices in the EU following MDR and MDD legislations.
Consultant Market Access & Pricing
In LatticePoint, Benedetta has been involved in several value-based indication evaluation and prioritization projects, assessing products’ values from scientific, clinical, and market potential perspectives. Understanding the indications and the competitive landscape, her goal is to support the development of clinical strategies and evidence-generation plans, ensuring the capture of the real unmet needs and evidence gaps.
She has experience in pricing and reimbursement strategies for different European countries, with specific expertise in market access in Italy. She is responsible for the payer panel database, with a large collection of key stakeholders ranging from payers, prescribers, and HTA advisors to medical key opinion leaders in the US, Europe, and parts of Asia.
Prior to consulting, Benedetta specialized in the field of medicinal chemistry. In particular, her projects were focused on the development of potential future drug candidates for the treatment of inflammatory diseases and antibiotic resistance.
Since joining LatticePoint, Vasiliki has been actively engaged in numerous value-based pricing projects encompassing a wide range of disease areas, including oncology, infectious diseases, and rare diseases. She has conducted primary research through organising and conducting payer interviews, as well as engaged in secondary research activities. Furthermore, she has contributed to development of reimbursement dossiers.
Vasiliki has amassed substantial experience in pricing and reimbursement strategies across various European countries, including EU4, UK, Nordics, Switzerland as well as regions outside Europe (ROW) and emerging markets, with a particular emphasis on combination therapies and the framework surrounding companion diagnostics.
Prior to her consultancy role, Vasiliki built a strong background in Biomedicine through her academic pursuits and her 2-year Postdoctoral stay in the Swiss Federal Institute of Technology (EPFL, Lausanne). During this period, she actively contributed to a range of in vivo and translational projects spanning diverse areas, such as aging, Chronic Kidney Disease, hepatosteatosis, Chronic Liver Disease, as well as bone metabolism and osteoporosis.
Estelle joined LatticePoint in 2022. She holds an M.Sc. in Human Biology from the University of Zurich (Switzerland), and she performed a Cifre Ph.D. in Cellular and molecular biology at the University of Caen-Normandie (France) in collaboration with Op2Lysis.
Estelle has a research background in Neurovascular diseases and thrombolysis. She worked on developing a new thrombolytic agent to be used in stroke. Before joining LatticePoint, Estelle worked as an MSL for HRA Pharma and as a research associate for Op2Lysis, where she oversaw the development of research protocol and preclinical development.
Agnes joined LatticePoint in 2023. Her educational foundation was laid at the Technical University of Munich in Germany, where she completed both her bachelor’s and master’s degrees in biochemistry. Her academic carrier continued at Utrecht University in the Netherlands, where she pursued her PhD.
Her research primarily revolved around the study of large biomolecular systems, with a special emphasis on the dynamic interactions of microtubules with microtubule-associated proteins. For example, Agnes studied the Tau protein which is associated with neurodegeneration and the MAP7 protein overexpressed in several cancers.
Martina joined LatticePoint in 2023. She holds a M.Sc. in Molecular Biology from the University of Padova (Italy) and a PhD in Molecular Biology from the University of Vienna (Austria).
Martina has a research background in immunology with a focus on the molecular regulation of the inflammatory response and on the role of innate immune cells in shaping the tumour microenvironment.